Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938250 | 0.83 | CYP1A2 (0.49) | POLBCYP1A2CYP2C9GAARAB9A | |
| SCHEMBL3055365 | 0.81 | CYP1A2 (0.47) | POLBCYP1A2CYP2C9GAARAB9A | |
| SCHEMBL352276 | 0.80 | GAA (0.53) | POLBGAAMEN1KMT2AHSD17B10 | |
| Hydrochloric Acid SCHEMBL5009791 | 0.78 | GAA (0.51) | POLBGAAMEN1KMT2AHSD17B10 | |
| SCHEMBL5150367 | 0.78 | CYP1A2 (0.45) | POLBCYP1A2CYP2C9GAARAB9A | |
| SCHEMBL19240419 | 0.78 | POLB (0.46) | POLBCYP1A2CYP2C9GAARAB9A | |
| SCHEMBL14072051 | 0.76 | POLB (0.34) | POLBCYP1A2CYP2C9GAARAB9A | |
| SCHEMBL15525136 | 0.75 | ALDH1A1 (0.55) | POLBCYP1A2CYP2C9GAARAB9A | |
| SCHEMBL6612159 | 0.74 | POLB (0.46) | POLBCYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL28541453 | 0.74 | CYP1A2 (0.46) | POLBCYP1A2CYP2C9GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117980293-A | Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof | 上海海和药物研究开发股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023036289-A1 | HYDROXAMIC ACID COMPOUND HAVING ENPP1 INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-03-16 | — | — | WO | disclosed |
| CN-1780835-B | Novel fused heterocycles and uses thereof | ASTRAZENECA AB | 2010-06-09 | — | — | CN | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1781673-B1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| EP-2094671-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| CN-1780835-A | Novel fused heterocycles and uses thereof. | ASTRAZENECA AB (SE) | 2006-05-31 | — | — | CN | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006018627-A1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018628-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1601673-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078758-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
| US-4189483-A | FUNGICIDE, INSECTICIDES, BACTERICIDES, MITICIDES, FOR PLANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | POLB 2413/4885CYP1A2 416/4885CYP2C9 40/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | POLB 1010/4885CYP1A2 37/4885CYP2C9 87/4885 |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | CYP11B2, HCCS, CYP11B1 | POLB 1155/4885CYP1A2 15/4885CYP2C9 36/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | POLB 1155/4885CYP1A2 15/4885CYP2C9 36/4885 |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | BRCA1, CYP1B1, CCNI | POLB 1916/4885CYP1A2 46/4885CYP2C9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.